DXB.AX
Price:
$0.505
Market Cap:
$281.72M
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs. It develops DMX-200 that is in two Phase 3 clinical trials for COVID respiratory complications; DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 for diabetic kidney disease; and DMX-700 for chronic obstructive pulmonary disease. The company is headquartered in Fitzroy, Australia.[Read more]
Industry
Biotechnology
IPO Date
1989-07-31
Stock Exchange
ASX
Ticker
DXB.AX
According to Dimerix Limited’s latest financial reports and current stock price. The company's current PE Ratio is -12.62. This represents a change of 155.98% compared to the average of -4.93 of the last 4 quarters.
The mean historical PE Ratio of Dimerix Limited over the last ten years is -10.81. The current -12.62 PE Ratio has changed 11.57% with respect to the historical average. Over the past ten years (40 quarters), DXB.AX's PE Ratio was at its highest in in the January 2011 quarter at 551.46. The PE Ratio was at its lowest in in the June 2015 quarter at -20.13.
Average
-10.81
Median
-10.22
Minimum
-17.06
Maximum
-4.22
Discovering the peaks and valleys of Dimerix Limited PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 256.73%
Maximum Annual PE Ratio = -4.22
Minimum Annual Increase = -55.84%
Minimum Annual PE Ratio = -17.06
Year | PE Ratio | Change |
---|---|---|
2024 | -14.06 | 95.44% |
2023 | -7.19 | -17.40% |
2022 | -8.71 | -9.66% |
2021 | -9.64 | -18.63% |
2020 | -11.85 | -30.55% |
2019 | -17.06 | 58.07% |
2018 | -10.79 | -28.28% |
2017 | -15.05 | 256.73% |
2016 | -4.22 | -55.84% |
2015 | -9.55 | -6.56% |
The current PE Ratio of Dimerix Limited (DXB.AX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-9.99
5-year avg
-10.29
10-year avg
-10.81
Dimerix Limited’s PE Ratio is less than Cynata Therapeutics Limited (-4.24), less than Oneview Healthcare PLC (-10.48), greater than Proteomics International Laboratories Limited (-13.70), greater than PharmAust Limited (-13.32), less than Minbos Resources Limited (-5.72),
Company | PE Ratio | Market cap |
---|---|---|
-4.24 | $51.81M | |
-10.48 | $216.15M | |
-13.70 | $90.39M | |
-13.32 | $111.93M | |
-5.72 | $53.35M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Dimerix Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Dimerix Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Dimerix Limited's PE Ratio?
How is the PE Ratio calculated for Dimerix Limited (DXB.AX)?
What is the highest PE Ratio for Dimerix Limited (DXB.AX)?
What is the 3-year average PE Ratio for Dimerix Limited (DXB.AX)?
What is the 5-year average PE Ratio for Dimerix Limited (DXB.AX)?
How does the current PE Ratio for Dimerix Limited (DXB.AX) compare to its historical average?